Discover the health-related quality of life findings from FRESCO-2¹, highlighting how Fruzaqla^®2 supports stability and delays deterioration, as analyzed through patient-centered tools.

Learn more about FRESCO-2, the global, randomised, double-blind, multi-centric phase III pivotal Fruzaqla®-study.

Explore the FRESCO-2 lay summary, co-written with patients to simplify key findings and present groundbreaking research in an accessible way.

DDW 2025 in San Diego - and you'll be there every day: with our Daily Reels!